Contemporary antiretroviral therapy (ART) has dramatically improved the prognosis of people living with HIV (PLWH) through the achievement of durable viral suppression and the consequent immune function restoration.

However, some heavily-treatment-experienced PLWH (HTE-PLWH) are unable to achieve viral suppression because of HIV-1 multi-drug resistance and/or drug intolerance. For these persons, who are at high risk of clinical progression, morbidity, and mortality, the proper management of the current and future antiretroviral options is critically important.

The PRESTIGIO Registry is an observational, prospective, multicenter, annual collection of data on clinical, laboratory, treatment, and virological characteristics of HTE-PLWH, regularly followed by several Italian Centers, with a documented resistance to at least 4 classes of antiretroviral drugs (NRTI, NNRTI, PI, INSTI). Aims of the PRESTIGIO Registry include the characterization of this fragile population and the connection between participating physicians in order to improve the overall management of the HTE-PLWH.

The first edition of the PRESTIGIO Registry Meeting (RING) has been conceived from these premises and we are confident that it will represent a unique opportunity to describe the state of art in the field of HIV multidrug resistance and to discuss the real-life management of HTE-PLWH.